ERBB2 and breast cancer: Regarding the clinical characteristics of BC patients, 21.7% (n=31) had HER2-negative and hormone receptor positive tumors, while 78.3% (n=112) of the patients had HER2-negative and hormone receptor negative tumors (TNBC).